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Abstract
Background: Protease inhibitor based antiretroviral therapy (PI-ART) was introduced in 1996 and has
greatly reduced the incidence of HIV-related morbidity and mortality in the industrialised world. PI-ART
would thus be expected to have a positive effect on health-related quality of life (HRQL). On the other
hand, HRQL might be negatively affected by strict adherence requirements as well as by short and long-
term adverse effects. The aim of this study was to assess the influence of two years of first generation PI-
ART on HRQL in patients with a relatively advanced state of HIV-infection. Furthermore, we wanted to
investigate the relation between developments in HRQL and viral response, self-reported adherence and
subjective experience of adverse effects in patients with PI-ART.
Methods: HRQL was measured by the Swedish Health-Related Quality of Life Questionnaire (SWED-
QUAL). Sixty-three items from the SWED-QUAL forms two single-item and 11 multi-item dimension
scales. For this study, two summary SWED-QUAL scores (physical HRQL composite score and emotional
HRQL composite score) were created through a data reduction procedure. At the 2-year follow-up
measurement (see below), items were added to measure adherence and subjective experience of adverse
effects. Demographic and medical data were obtained from specific items in the questionnaires and from
the medical files. Seventy-two patients who were among the first to receive PI-ART (indinavir or ritonavir
based) responded to the questionnaire before the start of PI-ART. Of these, 54 responded to the same
instrument after two years of treatment (13 had died, four had changed clinic and one did not receive the
questionnaire).
Results: The main findings were that the emotional HRQL deteriorated during two years of PI-ART, while
the physical HRQL remained stable. Multiple linear regression analyses showed that experience of adverse
effects contributed most to the deterioration of emotional HRQL.
Conclusion: In this sample of patients with relatively advanced state of HIV-infection, our data suggested
that a negative development of physical HRQL had been interrupted by the treatment and that the
emotional dimension of HRQL deteriorated during two years after start of PI-ART. Subjective experience
of adverse effects made a major contribution to the decrease in emotional HRQL. The results underline
the importance of including HRQL measures in the evaluation of new life prolonging therapies.
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Background
Protease inhibitor based antiretroviral therapy (PI-ART),
defined as the combination of at least two nucleoside ana-
logues with at least one protease inhibitor (PI) [1], was
introduced in 1996 and has greatly reduced the incidence
of HIV-related morbidity and mortality in the industrial-
ised world [2,3]. PI-ART would thus be expected to have a
positive effect on health-related quality of life (HRQL).
On the other hand, HRQL might be negatively affected by
strict adherence requirements as well as by short and long-
term adverse effects [4,5].
Several studies (cross-sectional or longitudinal) have
focused on the HRQL of HIV-positive individuals in dif-
ferent stages of the HIV infection and under different
treatment regimes. The results have varied but in general
HIV infection affects several physical, psychological and
social dimensions of HRQL and patients with sympto-
matic disease and/or an AIDS-defining complication are
more severely affected than those with other comparable
chronic diseases [6-8]. HRQL has been shown to be
related to the CD4 value, viral load and symptoms, so that
patients with a more advanced state of HIV infection
reported poorer HRQL [9-15]. Moreover, symptoms,
physical function, role function and sexual function dete-
riorated over time, while emotional domains were
unchanged or improved [9,10,16]. Only a few studies on
the influence of long-term (>1 year) PI-ART on the quality
of life have yet been published. Nieuwkerk et al. [17] com-
pared the development of HRQL during three different PI
based regimes and concluded that in terms of HRQL,
patients with higher CD4 values at start experienced less
benefit from the treatment. Burgoyne et al. [18,19] fol-
lowed HRQL in 41 patients with different treatment status
over a period of four years and found no overall change of
HRQL and that HRQL was less sensitive to CD4 changes
than to symptom changes as well as that change in HRQL
was somewhat related to change in social support.
The main aim of the present study was to investigate
HRQL before and after two years of first generation PI-
ART. The following research questions were addressed: (a)
Does HRQL change during two years of PI-ART? (b) Do
viral response, adherence, subjective experience of adverse
effects and initial CD4 count predict changes in HRQL
during two years of PI-ART?
Methods
Data collection
Subjects
The study was performed at the Department of Venhälsan
at South Stockholm General Hospital, Sweden. A conven-
ient sample of 72 subjects (70 men and 2 women) in an
advanced state of HIV infection and who were among the
first patients to receive PI-ART in Sweden responded to the
HRQL instrument described below before the start of PI-
ART (pre PI-ART). HIV infection was documented by at
least two laboratory tests (two repeated ELISA tests or one
ELISA test and one Western Blot). The patients were
treated according to best clinical practice and the partici-
pant's physician chose the drug combination of the PI-
ART (at least 2 nucleoside analogue reverse transcriptase
inhibitors and either indinavir (n = 55) or ritonavir (n =
17) at start). Approximately two years after the introduc-
tion of PI-ART (follow-up; mean 25.1 months, standard
deviation (SD) 2.8 months, post initiation), 54 of the 72
subjects (75 %) completed the follow-up measure. Thirteen
patients had died, four had changed clinic and one did
not receive the follow-up questionnaire.
The Swedish Health-Related Quality of Life Questionnaire (SWED-
QUAL)
The patients completed the SWED-QUAL at the pre PI-ART
and two-year follow-up visits. SWED-QUAL was developed
by Brorsson et al. [20] from the measures used in the US
Medical Outcomes Study (MOS) [21-24]. The question-
naire, which is designed to measure HRQL, consists of 70
items, of which 63 forms two single-item and 11 multi-
item dimension scales of Likert type: physical functioning
(7 items), mobility (1 item), satisfaction with physical
ability (1 item), role limitations due to physical health (3
items), pain (6 items), emotional well-being: positive
affect (i.e. positive feelings; 6 items), emotional well-
being: negative affect (i.e. negative feelings; 6 items), role
limitations due to emotional health (3 items), sleep prob-
lems (7 items), satisfaction with family life (relations with
parents, siblings, children etc.; 4 items), relation to part-
ner (6 items), sexual functioning (4 items) and general
health perception (9 items). In the present study, the rela-
tion to partner section was slightly modified to make it
suitable for the investigated group (i.e. the word "spouse"
was replaced by "partner"). Each scale is transformed into
a 0–100 index; the higher the score, the better the per-
ceived HRQL. In a general population sample, the inter-
nal-consistency reliability coefficients (Cronbach's α)
ranged from 0.79 to 0.89 [20]. Brorsson et al. have also
reportedpreliminary support for the construct validity
[20]. The instrument has been used in our previous study
of HIV-positive subjects in Sweden [25].
A factor analysis (see below) was performed on a merged
material from three groups of patients: (a) the group
described above at pre PI-ART (n = 72), (b) a previously
described group of protease inhibitor naïve HIV patients
(n = 73) [25] and (c) an unpublished material of 164 HIV-
negative men who have sex with men visiting our infor-
mation and screening clinic for sexually transmitted dis-
eases (own unpublished data).
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Adherence/adverse effects
At the follow-up, the patients' adherence and drug-related
adverse effects were examined. Adherence was assessed by
asking the following question, modified from Morisky et
al. [26]: "How many times during the last month did you
skip doses of your HIV medication for the following rea-
sons: because you felt so good that it did not matter,
because you felt worse due to the medication or because
you forgot?" For each of the three given reasons the
patients were asked to rate the number of missed doses on
a scale with five alternatives (1 = 0 doses, 2 = 1–2 doses, 3
= 3–5 doses, 4 = 6–9 doses or 5 = >9 doses). Patients were
classified as non-adherent if they indicated >9 missed
doses in at least one of the three mentioned categories (i.e.
indicating 90% adherence or less) or if they indicated
missed doses in all three categories.
The subjective experience of medication-related adverse
effects was addressed in one question, which asked the
patients to rate their global experience of adverse effects
during the past month on a 10 cm visual analogue scale
(VAS) ranging from "none at all" to "severe".
Laboratory measures
Lymphocyte subsets were determined, using routine flow
cytometry [27], at least every 3–4 months. The level of
HIV-1 RNA in plasma was quantified at the Swedish Insti-
tute for Infectious Disease Control by a commercially
available reverse transcriptase polymerase chain reaction
(PCR)-based assay (HIV Monitor; Roche Diagnostic Sys-
tems, Branchburg New Jersey, USA). The level of quantifi-
cation at the time of the study was 500 viral copies ml-1.
Viral outcome
On the basis of the participants' long-term virologic out-
come to PI-ART, they were subdivided into viral respond-
ers and viral non-responders. Viral responders were
defined as participants who, after the first 3 months of PI-
ART, had either HIV RNA less than 500 copies ml-1 in
more than 75% of the analysed samples or a continuous
decrease in HIV RNA to below 500 copies ml-1 before 18
months. All other participants were regarded as viral non-
responders [28].
Demographic and medical data
Demographic and medical data were obtained from spe-
cific items in the questionnaires and from the medical
files.
Statistical methods
Statistical calculations were performed with the assistance
of the personal-computer program SPSS for Windows,
version 11.0.0. The criterion for statistical significance was
p < 0.05. Since some parameters did not fulfil the assump-
tions of a normal distribution, the Wilcoxon signed ranks
test [29] was used to compare differences between two
related groups (i.e. pre PI-ART versus follow-up).
In order to achieve data reduction to create composite
scores for use in multiple regression analyses of the mate-
rial, a rotated component matrix analysis [30] was per-
formed on the scores from ten of the 13 SWED-QUAL
scales (i.e. those measuring physical and emotional
health). The following scales were used in the factor anal-
ysis: physical functioning, mobility, satisfaction with
physical ability, role limitations due to physical health,
pain, emotional well-being: positive affect, emotional
well-being: negative affect, role limitations due to emo-
tional health, sleep problems and sexual functioning. The
analysis resulted in two factors: (a) physical HRQL com-
posite score, i.e. PCS, comprising the averaged scores of
the SWED-QUAL scales physical functioning, mobility,
satisfaction with physical ability, pain, role limitations
due to physical health and sexual functioning, and (b)
emotional HRQL composite score, i.e. ECS, comprising
the averaged scores of the SWED-QUAL scales role limita-
tions due to emotional health, positive affect, negative
affect and sleep problems (Table 1). These two factors
explained 65 % of the total variance.
A set of hierarchical multiple linear regression analyses
[31] were performed to investigate whether the initial
CD4 value, viral response, adherence and subjective expe-
rience of adverse effects predicted the change in HRQL.
The two analyses (one for PCS and one for ECS) were con-
ducted in two forced steps with the follow-up PCS and ECS
as dependent variables. The pre PI-ART PCS and ECS,
respectively, were entered in the first step, while the three
variables viral response, adherence and subjective experi-
Table 1: Rotated factor loading (varimax) of the principal 
component analysis (n = 309)
Rotated factor loadings
PCS ECS
SWED-QUAL Scale
Physical functioning 0.92 0.07
Mobility 0.83 0.04
Satisfaction with physical ability 0.79 0.24
Pain 0.56 0.45
Role limitations due to physical health 0.66 0.46
Sexual functioning 0.63 0.32
Role limitations due to emotional health 0.33 0.75
Emotional well-being, positive affect 0.08 0.81
Emotional well-being, negative affect 0.08 0.85
Sleep problems 0.32 0.70
PCSPhysical HRQL composite score; ECSEmotional HRQL composite 
score
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ence of adverse effects were entered in the second step
together with the initial CD4 value.
Ethical approval
The study was approved by the Local Ethical Committee
at Huddinge University Hospital. Information about the
study was given to the subjects in connection with an ordi-
nary, scheduled visit to the clinic.
Results
Demographic and medical data
At pre PI-ART, the mean age of the 72 patients was 41 (SD
9, range 23 – 65) years, 59 were of Swedish origin, 61 had
prior antiretroviral treatment with only nucleoside ana-
logue reverse transcriptase inhibitors, 32 had a CD4 count
of <200 × 106 cells l-1 and 28 had an AIDS diagnosis. Fur-
ther demographic and medical data are shown in Table 2.
Changes from pre PI-ART to follow-up
From the pre PI-ART to the follow-up, the CD4 count of the
surviving patients increased from a median (Md) of 150
(range 1 – 660) × 106 cells l-1 to 325 (range 5 – 840) × 106
cells l-1 (p < 0.001) and the HIV-1 RNA level decreased
from 4.90 (range 2.70 – 6.00) log10 copies ml
-1 to 2.70
(range 2.70 – 6.31) log10 copies ml
-1 (p < 0.001). Thirty
patients had switched PI during the first two years of PI-
ART. A total of 36 subjects were classified as viral respond-
ers and 18 as viral non-responders.
The patients' emotional well-being deteriorated during the first two 
years of PI-ART
The pre PI-ART and follow-up results of the composite
scores and the single SWED-QUAL scales are shown in
Table 3. The ECS decreased from pre PI-ART to follow-up
(Md 71.2, interquartile range (IQR) 47.1 – 86.9 versus Md
63.6, IQR 41.0 – 77.3; p < 0.01;). A comparison of the sin-
gle SWED-QUAL scales at pre PI-ART with the same scales
at follow-up revealed statistically significant decreases in
the SWED-QUAL scales role limitations due to emotional
health (pre PI-ART Md 88.9, IQR 66.7 – 100 versus follow-
up Md 77.8, IQR 50.0 – 100; p < 0.05) and emotional
well-being: negative affect (pre PI-ART Md 62.5, IQR 37.5
– 94.8 versus follow-up Md 50.0, IQR 25.0 – 75.0; p < 0.01;
Table 3). The effect sizes of the change were 0.34 for the
PCS, 0.36 for role limitations due to emotional health and
0.37 for emotional well-being: negative affect.
Subjective experience of adverse effects contributed to deteriorated 
emotional HRQL at follow-up
Forty-seven (87 %) of the 54 patients were classified as
adherent and seven (13 %) as non-adherent. The mean
VAS score for subjective experience of adverse effects at fol-
low-up was 3.39 (SD 2.95, Md 2.57, IQR 0.79 – 5.84) cm
on a 10 cm scale.
Two hierarchical multiple regression analyses were per-
formed to investigate whether the change in physical and
Table 2: Demographic and medical data regarding a Swedish sample of HIV-infected persons before the start of PI-ART (n = 72)
No. of subjects Percentage
Mode of transmission
Male to male 69 96
Female to male/male to female 3 4
Working status
Full or part time work/studies 36 50
Sick leave or disability pension 31 43
Not stated 5 7
Education
Compulsory school 13 18
Upper secondary school/high school 27 38
University studies 27 38
Not stated 5 7
Having a partner:
Yes/no 30/41 42/57
not stated 1 1
CD4 count, cells × 106 l-1: median 127
range 1–660
HIV RNA, log10 copies ml
-1: median 4.87
range 2.70–6.18
Time since first start of antiretroviral treatment, months: mean 33
SD 31.6
PI-ARTProtease inhibitor based antiretroviral therapy; SDStandard deviation
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Table 3: The Swedish Health-Related Quality of Life Questionnaire (SWED-QUAL) results before and after 2 years of protease 
inhibitor based antiretroviral therapy (pre PI-ART and follow-up respectively). The higher the score the better the health-related 
quality of life (n = 54)
Score
Pre PI-ART Median (IQR) Follow-up Median (IQR) P-valuea
Physical HRQL composite score (PCS) 79.3 (64.5–92.5) 77.2 (58.4–92.9) NS
Emotional HRQL composite score (ECS) 71.2 (47.1–86.9) 63.6 (41.0–77.3) <0.01
Physical functioning 95.2 (81.0–95.2) 95.2 (84.5–100) NS
Mobility 100 (66.7–100) 100 (66.7–100) NS
Satisfaction with physical ability 66.7 (33.3–83.3) 66.7 (33.3–100) NS
Pain 100 (53.8–100) 100 (84.7–100) NS
Role limitations due to physical health 66.7 (55.6–100) 88.9 (50.0–100) NS
Sexual functioning 75.0 (41.7–91.7) 58.3 (41.7–91.7) NS
Role limitations due to emotional health 88.9 (66.7–100) 77.8 (50.0–100) <0.05
Emotional well-being, positive affect 72.9 (47.9–83.3) 62.5 (37.5–83.3) NS
Emotional well-being, negative affect 62.5 (37.5–94.8) 50.0 (25.0–75.0) <0.01
Sleep problems 67.9 (39.3–87.5) 57.1 (36.6–75.0) NS
Satisfaction with family life 72.9 (49.5–90.6) 72.9 (55.7–85.4) NS
Relation to partner 87.5 (75.0–100) 79.2 (52.1–95.8) NS
General health perception 55.6 (36.1–75.0) 63.9 (38.9–80.6) NS
aWilcoxon signed ranks test, change from pre PI-ART to follow-up; NSNon significant; IQRInterquartile range; HRQLHealth-related quality of life
Table 4: Hierarchical multiple linear analyses of the influence of initial CD4 value and the variables viral response, subjective 
experience of adverse effects and adherence on the change in PCS and ECS from before start (pre PI-ART) to after two year of 
treatment (follow-up)
Follow-up PCS Follow-up ECS
Step 1 Partial correlationa Partial correlationa
Pre PI-ART PCS 0.722*** -
Pre PI-ART ECS - 0.681***
R2 0.605*** 0.456***
F 78.26 42.72
d.f. (regression;residual) 1;51 1;51
Step 2 Partial correlation Partial correlation
Viral response 0.202 0.076
Adherence 0.167 0.235
Adverse effects 0.091 -0.366*
Pre PI-ART CD4 value -0.043 -0.024
R2-change 0.028 0.128*
F-change 0.91 3.63
d.f. (regression;residual) 4;47 4;47
PCSPhysical HRQL composite score; ECSEmotional HRQL composite score; PI-ARTProtease inhibitor based antiretroviral therapy; apartial correlation 
of the final model (step 2); *p < 0.05; ***p < 0.001
Health and Quality of Life Outcomes 2005, 3:32 http://www.hqlo.com/content/3/1/32
Page 6 of 8
(page number not for citation purposes)
emotional HRQL composite scores could be predicted by
initial CD4 count, viral response, adherence and subjec-
tive experience of adverse effects (Table 4). Only the ECS
model showed a statistically significant R2 change; that is,
the subjective experience of adverse effects predicted a
decrease in the emotional HRQL.
Internal consistency of the SWED-QUAL scales
Cronbach's α reliability estimates for the 11 SWED-QUAL
multi-item scales for the pre PI-ART and follow-up ranged
between 0.74 and 0.92 indicating good internal consist-
ency. The internal consistency for the two HRQL compos-
ite scores was for the PCS α 0.88 and 0.85 (pre PI-ART and
follow-up, respectively) and for the ECS α 0.91 and 0.89
(pre PI-ART and follow-up, respectively).
Discussion
In this study we used the SWED-QUAL instrument to
investigate the HRQL of 54 relatively advanced HIV
patients before and after two years of first generation PI-
ART in a setting where protease inhibitors were intro-
duced. We also studied the patients' viral outcome, self
reported adherence and subjective experience of adverse
effects and the relationship between these variables and
the development in HRQL. To minimise multiple com-
parisons, a set of linear regression models were used. To
increase the power to detect relations as a result of these
models, we created two SWED-QUAL composite scores
(PCS and ECS) through a data reduction procedure.
The main findings from the present study were that the
physical HRQL remained stable while the emotional
HRQL deteriorated for two years of first generation PI-ART
and that subjective experience of adverse effects was the
strongest predictor of the deterioration in emotional
HRQL ratings.
The present study thus suggests that first generation PI-
ART interrupted the progressive negative development of
the physical domain of HRQL that has been reported in
studies performed before the introduction of PI-ART
[9,10,16,32,33]. Our findings are consistent with those of
Goujard et al. [34] and Burgoyne et al. [18] who also failed
to detect any changes in HRQL after one and a half and
four years, respectively, when monitoring patients in a
period after PI-ART had become available.
The somewhat surprising decrease in emotional health
found in the present study has, to our knowledge, not
been reported in other longitudinal studies of PI-ART.
Longitudinal studies performed before the introduction
of PI-ART have, in general, showed stable or improved
mental/emotional health over time [9,10,16,35]. We also
found stable scores in the emotional domain of HRQL in
a previous pre PI-ART era study, where patients with no or
only single drug antiretroviral therapy were followed for
two years (own unpublished data). However, a study
investigating the HRQL of patients receiving didanosine
monotherapy or in combination with delavirdine (not
approved in Europe due to side effects) showed slightly
declining mental health scores for up to two years after the
start of the trial [33]. After the introduction of PI-ART,
improvements in depressive symptoms and mental health
was reported in a shorter time period, i.e. after up to one
year following the addition of a PI to existing antiretrovi-
ral therapy [36,37]. Similarly, Rabkin et al. [38] found a
reduction in psychological distress and clinical depression
during a two-year period when PI-ART became widely
available. In the latter study, however, PI-ART was intro-
duced to the cohort continuously during the follow-up,
resulting in a mean time with PI-ART shorter than two
years (i.e. the analysis did not evaluate patients before and
after start of PI-ART in a consistent manner). From a
longer term perspective, however, emotional HRQL was
found to be stable over a four-year period [18].
When we further investigated the relation between the
change in HRQL and the variables viral response, adher-
ence, subjective experience of adverse effects and baseline
CD4 value, our study showed that it was the subjective
experience of adverse effects that contributed most to the
deterioration in the emotional HRQL. It should be
stressed that our measure of adverse effects was a global
single item, where the patients were asked to rate their
total perception of adverse effects during the previous
month and that we did not sub-analyse this experience
further into different symptoms. However, the negative
impact of perceived side effects/symptoms on HRQL, is
confirmed in a great number of quantitative investiga-
tions [12,18,37-42]. Also, the results from our quantita-
tive study agreed with those of a qualitative study that
aimed to elicit the patients' real-life descriptions of their
experience of combination therapy. Erlen & Mellors [43]
found that side effects were one of the major problems
associated with the therapy. Furthermore, symptoms or
adverse events have been shown to be related to medica-
tion adherence [44,45]. In order to improve HRQL and
adherence, it is therefore crucial to find treatment combi-
nations and strategies that minimise these negative effects
and to individualize treatment. The simplified and less
toxic treatment regimes available today, with antiretrovi-
ral therapy based on three nucleoside analogue reverse
transcriptase inhibitors or nucleoside analogues com-
bined with non-nucleoside analogue reverse transcriptase
inhibitors or ritonavirboosted PIs once or twice daily [1],
may be less liable to have a negative impact on HRQL.
This was indicated in a randomised study comparing two
nucleoside analogue reverse transcriptase inhibitors com-
bined with either a PI or efavirenz, over a one year period
and where the combination with efavirenz had a better
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influence on HRQL than the combination with the PI
[46]. Similarly, Carrieri et al. [37] found a positive devel-
opment of HRQL in patients switching to a non-PI-con-
taining therapy, as compared to patients continuing stable
PI-ART. However, these aspects need to be further investi-
gated and there is a need for further study of the effect of
different treatment regimes on HRQL, in experienced as
well as naïve patients.
Certain study limitations should be emphasized when
interpreting the present results. Firstly, the small sample
may mean that the study failed to detect further relations
between the investigated variables. Secondly, a large pro-
portion of the investigated patients were in an advanced
state of their HIV infection and many had previous expe-
rience of antiretroviral monotherapy. The inferences
drawn from this study may not be applicable to ART naïve
patients starting antiretroviral therapy in a less advanced
state of the disease. Today treatment is started when cer-
tain laboratory criteria are fulfilled and before symptoms,
including AIDS-defining disease, are at a high risk of
appearing. Thirdly, our study population may not be
totally representative of all patients receiving PI-ART. The
majority of our patients were well-educated males with a
homosexual route of transmission. The influence on
HRQL may be different for female patients or patients
with other educational status or routes of transmission. It
should be noted that we chose to consider viral outcome
of the treatment in a longitudinal context, i.e. viral
response defined by repeated HIV RNA measures over up
to 18 months. The impact on the development of HRQL
might have been different if only one single measure of
viral load at follow-up had been taken into account.
Conclusion
In this sample of mainly advanced patients, the emotional
dimension of HRQL had deteriorated for two years after
the start of first generation PI-ART, and the subjective per-
ception of adverse effects made a major contribution to
this decrease.
The results of the present study show the importance of
studying HRQL in a situation where there is a desperate
need for life-saving new therapies. Therefore, consistently
taking HRQL into account when treating HIV patients is
of the utmost importance. Finding treatment combina-
tions and strategies with the least negative long-term
influence on HRQL is essential at a time when those hav-
ing access to antiretroviral combination therapy have a
dramatically increased life span. Furthermore, consider-
ing the current numerous treatment options together with
the fluctuations in HRQL over time, further short and
long-term investigations of HRQL in patients receiving
antiretroviral therapy are of the utmost importance.
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